Share This Article:

Dyscirculatory Angiopathy of Alzheimer's Type

Full-Text HTML Download Download as PDF (Size:6861KB) PP. 57-68
DOI: 10.4236/jbbs.2011.12008    4,585 Downloads   9,367 Views   Citations


Purpose: We assess the significance of dyscirculatory angiopathy of Alzheimer’s type (DAAT) in identify- ing the predisposition to the development and diagnosis of Alzheimer’s disease (AD) different stages. Meth- ods: 108 patients took part in the research:1) 49 aged 34-79 suffering from AD or running an increased risk of its development (those not diagnosed with AD but having growing memory disorders without any mani- festations of dementia or specific cognitive impairments, and having 2 or more immediate relatives with AD) - Test Group; 2) 59 aged 28-78 suffering from different types of brain lesions accompanied by dementia but not suffering from AD or corresponding to their age norm - Control Group. All the patients underwent MRI, CT with subsequent calculation of the temporal lobes atrophy degree, brain scintigraphy (SG), rheoencepha- lography (REG), and MUGA. Results: Characteristic features of patients with an increased risk of AD as well as at its various stages are: 1) Temporal lobes and hippocampus atrophy ranging from 4% among those with an increased risk of AD to 62% among those at its advanced stages; 2) DAAT manifestations: reduction of the capillary bed in the temporal and frontoparietal regions with the development of multiple arterioven- ous shunts of the same localization and correspondent early venous discharge accompanied by venous stasis on the border of the frontal and parietal region; 3) DAAT phenomena equally develop both among those with an increased risk of developing AD and those at various AD stages. Similar changes are not observed among Control Group patients with other brain lesions, regardless of the severity of dementia, as well as among practically healthy people of the corresponding age group. Conclusion: Timely identification of the above- mentioned changes can reveal a predisposition to AD development long before its initial manifestations, and it allows differentiating AD from other diseases attended by dementia. In both cases, timely diagnosis allows beginning timely treatment and thus achieving more stable results.

Cite this paper

I. Maksimovich, "Dyscirculatory Angiopathy of Alzheimer's Type," Journal of Behavioral and Brain Science, Vol. 1 No. 2, 2011, pp. 57-68. doi: 10.4236/jbbs.2011.12008.


[1] Alzheimer’s Association, “Alzheimer’s Disease Facts and Figures 2007 - A Statistical Abstract of US Data on Alz-heimer’s Disease,” 2007.
[2] Alzheimer’s Association, “Alzheimer’s Disease Facts and Figures 2009,” 2009.
[3] Alzheimer’s Association, “Alzheimer’s Disease Facts and Figures 2010,” 2010.
[4] Alzheimer’s Association, “Generation Alzheimer’s: The Defining Disease of the Baby Boomers,” 2011.
[5] J. Corey-Bloom, L. Thal, D. Galasko, et al. “Diagnosis and Evaluation of Dementia,” Neurology, Vol. 45, No. 2, 1995, pp. 211-218.
[6] B. Carpenter and J. Dave, “Disclosing a Dementia Diagnosis: A Review of Opinion and Practice, and a Proposed Research Agenda,” Geronotologist, Vol. 44, No. 2, 2004, pp. 149-158.
[7] Z. Lao, D. Shen, Z. Xue, et al. “Morphological Classification of Brains via High-dimensional Shape Transformations and Machine Learning Methods,” Neuroimage, Vol. 21, No. 1, 2004, pp. 46-57.
[8] G. Waldemar, B. Dubois, M. Emre, J. Georges, I. G. McKeith, M. Rossor, P. Scheltens, P. Tariska and B. Winblad, “Recommendations for the Diagnosis and Management of Alzheimer’s Disease and Other Disorders Associated with Dementia: EFNS Guideline,” European Journal of Neurology, Vol. 14, No. 1, 2007, pp. e1-26. doi:10.1111/j.1468-1331.2006.01605.x
[9] C. R. Jack, M. D. Bentley, C. K. Twomey and A. R. Zinsmeister, “MR Imaging-based Volume Measurements of the Hippocampal Formation and Anterior Temporal Lobe: Validation Studies,” Radiology, Vol. 176, No. 1, 1990, pp. 205-209.
[10] C. R. Jack, R. C. Petersen, Y. C. Xu, et al. “Medial Tem- poral Atrophy on MRI in Normal Aging and Very Mild Alzheimer’s Disease,” Neurology, Vol. 49, No. 3, 1997, pp. 786-794.
[11] C. R. Jack, R. C. Petersen, Y. C. Xu, et al. “Prediction of AD with MRI-based Hippocampal Volume in Mild Cognitive Impairment,” Neurology, Vol. 52, No. 7, 1999, pp. 1397-1403.
[12] I. V. Maksimovich, L. N. Gotman and S. M. Masyuk, “Method of Determining Dimensions of Temporal Brain Lobes in Patients Suffering from Alzheimer’s Disease,” Russian Patent, 2006, 2306102.
[13] I. V. Maksimovich, “Possibilities of Modern Computed Tomography of Brain in Alzheimer’s Disease Diagnosis,” The Neurologic Bulletin, Vol. XLI, No. 1, 2009, pp. 5-10.
[14] P. Pietrini, G. E. Alexander, M. L. Furey, et al. “Cere- bral Metabolic Response to Passive Audiovisual Stimula- tion in Patients with Alzheimer’s Disease and Healthy Volunteers Assessed by PET,” Journal of Nuclear Medicine, Vol. 41, 2000, pp. 575-583.
[15] N. Okamura, H. Arai, M. Higuchi, et al. “[18F] FDG-PET Study in Dementia with Lewy Bodies and Alz- heimer’s Disease,” Progress in Neuropsychopharmacology & Biological Psychiatry, Vol. 25, No. 2, 2001, pp. 447-456. doi:10.1016/S0278-5846(01)80005-1
[16] A. J. Saykin and H. A. Wishart, “Mild Cognitive Impair- ment: Conceptual Issues and Structural and Functional Brain Correlates,” Seminars in Clinical Neuropsychiatry, Vol. 8, No. 1, 2003, pp. 12-30. doi:10.1053/scnp.2003.50002
[17] A. J. Saykin, H. A. Wishart, L. A. Rabin, et al. “Older Adults with Cognitive Complaints Show Brain Atrophy Similar to that of Amnestic MCI,” Neurology, Vol. 12, No. 67, 2006, pp. 834-842. doi:10.1212/01.wnl.0000234032.77541.a2
[18] L. Shen, H. A. Fipri, A. J. Saykin and J. D. West, “Parametric Surface Modeling and Registration for Comparison of Manual and Automated Segmentation of the Hippocampus,” Hippocampus, Vol. 19, No. 6, 2009, pp. 588-595. doi:10.1002/hipo.20613
[19] R. Mayeux, C. Reitz, A. M. Brickman, M. N. Haan, J. J. Manly, et al. “Operationalizing Diagnostic Criteria for Alzheimer’s Disease and Other Age-related Cognitive Impairment - Part 1,” Alzheimers & Dementia, Vol. 7, No. 1, 2011, pp. 15-34. doi:10.1016/j.jalz.2010.11.005
[20] S. Seashadri, A. Beaser, R. Au, P. A. Volf, D. A. Evans, et al. “Operationalizing Diagnostic Criteria for Alzheimer’s Disease and Other Age-related Cognitive Impairment - Part 2,” Alzheimers & Dementia, Vol. 7, No. 1, 2011, pp. 35-52. doi:10.1016/j.jalz.2010.12.002
[21] B. J. Small, E. Gagnon and B. Robinson, “Early Identification of Cognitive Deficits: Preclinical Alzheimer’s Disease and Mild Cognitive Impairment,” Geriatrics, Vol. 62, No. 4, 2007, pp. 19-23.
[22] R. N. Kalaria, “Cerebral Vessels in Aging and Alz- heimer’s Disease,” Pharmacology & Therapeutics, Vol. 72, No. 3, 1996, pp. 193-214. doi:10.1016/S0163-7258(96)00116-7
[23] G. Rodriguez, P. Vitali, P. Calvini, et al. “Hippocampal Perfusion in Mild Alzheimer’s Disease,” Psychiatry Research, Vol. 100, No. 2, 2000, pp. 65-74.
[24] R. N. Kalaria, “Small Vessel Disease and Alzheimer’s Dementia: Pathological Considerations,” Cerebrovascular Diseases, Vol. 13, No. 2, 2002, pp. 48-52. doi:10.1159/000049150
[25] I. V. Maksimovich “Changes in Angioarchetectonics of Brain at Alzheimer’s Disease,” The Neurologic Bullet, Vol. XLI, No. 2, 2009, pp. 9-14.
[26] G. A. Bateman, C. R. Levi, P. Schofield, Y. Wang and E. C. Lovett, “Quantitative Measurement of Cerebral Haemodynamics in Early Vascular Dementia and Alz- heimer’s Disease,” Journal of Clinical Neuroscience, Vol. 13, No. 5, 2006, pp. 563-568. doi:10.1016/j.jocn.2005.04.017
[27] N. A. Johnson, G. H. Jahng, M. W. Weiner, B. L. Miller, H. C. Chui, W. J. Jagust, M. L. Gorno-Tempini and N. Schuff, “Pattern of Cerebral Hypoperfusion in Alzheimer Disease and Mild Cognitive Impairment Measured with Arterial Spin-Labeling MR Imaging: Initial Experience,” Radiology, Vol. 234, No. 3, 2005, pp. 851-859. doi:10.1148/radiol.2343040197
[28] W. Chen, X. Song, S. Beyea, R. D’Arcy, Y. Zhan and K. Rockwood, “Advances in Perfusion Magnetic Resonance Imaging in Alzheimer’s Disease,” Journal of Alzheimer’s & Dementia, Vol. 7, No. 2, 2011, pp. 185-196.
[29] D. R. Theal, W. S. Griffin, R. A. de Vos and E. Ghebre- medhin, “Cerebral Amyloid Angiopathy and Its Relationship to Alzheimer’s Disease,” Acta Neuropathologica, Vol. 115, No. 6, 2008, pp. 599-609.
[30] J. Zaghi, B. Goldenson, M. Inayathullah, A. S. Lossinsky, A. Masoumi, et al. “Alzheimer’s Disease Macrophages Shuttle Amyloid-Beta from Neurons to Vessels, Contri- buting to Amyloid Angiopathy,” Acta Neuropathological, Vol. 117, No. 2, 2009, pp. 111-124. doi:10.1007/s00401-008-0481-0
[31] J. C. Morris, “The Clinical Dementia Rating (CDR): Current Version and Scoring Rule,” Neurology, Vol. 43 No. 11, 1993, pp. 2412-2414.
[32] I. V. Maksimovich and L. N. Gotman, “Method of Complex Radiation Diagnostics at Preclinical and Clinical Stages of Alzheimer’s Disease,” Russian Patent, 2006, No. 2315559. DOC&locale=en_EP&FT=D&CC=RU&NR=2315559C1&KC=C1
[33] I. V. Maksimovich, “Radiodiagnostics of Alzheimer’s Disease,” Diagnostics and Intervention Radiology, Vol. 2, No. 4, 2008, pp. 27-38.
[34] S. Burgmans, M. P. Van Boxtel, E. F. Vuurman, F. Smeets, E. H. Gronenschild, H. B. Uylings and J. Jolles, “The Prevalence of Cortical Gray Matter Atrophy may be Overestimated in the Healthy Aging Brain,” Neuropsy- chology, Vol. 23, No. 5, 2009, pp. 541-550. doi:10.1037/a0016161
[35] L. A. van de Pol, F. Verhey, G. B. Frisoni, M. Tsolaki, P. Parapostolou, et al. “White Matter Hyperintensities and Medial Temporal Lobe Atrophy in Clinical Subtypes of Mild Cognitive Impairment: The DESCRIPA Study,” Journal of Neurology, Neurosurgery & Psychiatry, Vol. 80, No. 10, 2009, pp. 1069-1074. doi:10.1136/jnnp.2008.158881
[36] A. Viswanathan, W. A. Rocca and C. Tzourio, “Vascular Risk Factors and Dementia: How to Move Forward?” Neurology, Vol. 27, No. 72, 2009, pp. 368-374.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.